Health Technology

Eisai Co., Ltd.

In the news

Japan and Western drugmakers launch $1bn fund against superbugs Jul 10, 2020
Japan's Eisai to launch clinical trial for coronavirus treatment Jul 1, 2020
Corporate inertia stops Japan from moving annual meetings online Jun 13, 2020
With profits rolling in, corporate Japan trims its workforce Feb 9, 2020
Governance demands chip away at Japanese cross-shareholdings Jul 8, 2019

Business Summary

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2022	JPY	USD
Revenue	756,226M	6,729.62M
Gross Profit	569,791M	5,070.54M
Operating income	59,623M	530.58M
Income before tax	54,458M	484.61M
Net income	47,954M	426.74M
EBITDA	98,021M	872.28M
Diluted EPS	167.24	1.48
Dividends Per Share	160	1.42
Total Assets	1,239.31B	10,210.62M
Total liabilities	467,781M	3,854.01M
Total equity	748,821M	6,169.48M
Operating cash flow	117,590M	1,046.42M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	600,054M	642,834M	695,621M	645,942M	756,226M
Gross Profit	386,599M	446,436M	510,352M	465,186M	569,791M
Operating income	75,595M	99,921M	138,679M	56,543M	59,623M
Income before tax	76,803M	89,454M	128,063M	52,551M	54,458M
Net income	51,845M	63,386M	121,767M	42,119M	47,954M
EBITDA	101,778M	126,762M	172,379M	92,842M	98,021M
Diluted EPS	180.97	221.11	424.79	146.90	167.24
Dividends Per Share	150	150	160	160	160
Total Assets	1,049.03B	1,071.52B	1,062.14B	1,090.00B	1,239.31B
Total liabilities	434,934M	419,539M	359,509M	362,067M	467,781M
Total equity	593,582M	628,120M	678,127M	703,183M	748,821M
Operating cash flow	149,649M	103,714M	102,782M	73,853M	117,590M

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	5,414.06M	5,796.79M	6,397.94M	6,090.49M	6,729.62M
Gross Profit	3,488.14M	4,025.76M	4,693.93M	4,386.17M	5,070.54M
Operating income	682.06M	901.04M	1,275.49M	533.13M	530.58M
Income before tax	692.96M	806.65M	1,177.85M	495.49M	484.61M
Net income	467.77M	571.58M	1,119.94M	397.13M	426.74M
EBITDA	918.30M	1,143.08M	1,585.44M	875.39M	872.28M
Diluted EPS	1.63	1.99	3.90	1.38	1.48
Dividends Per Share	1.35	1.35	1.47	1.50	1.42
Total Assets	9,863.94M	9,680.80M	9,838.72M	9,864.33M	10,210.62M
Total liabilities	4,089.64M	3,790.38M	3,330.17M	3,276.62M	3,854.01M
Total equity	5,581.39M	5,674.84M	6,281.57M	6,363.64M	6,169.48M
Operating cash flow	1,350.22M	935.24M	945.33M	696.34M	1,046.42M

Valuation Measures

Mar 2022
PER	33.89
ROA	4.11%
ROE	6.60%
Operating margin	7.88%
Profit margin	6.34%

Key executives

Chief Executive Officer & Representative Director: Haruo Naito
COO, Representative Executive Officer & Head-China: Yasushi Okada
Chief Financial Officer & Chief IR Officer: Tatsuyuki Yasuno
Chief Medical & Chief Clinical Officer-Neurology: Lynn D. Kramer
Executive Officer & Head-Global IT Headquarters: Keisuke Naito

Shareholders

Wellington Management Co. LLP (8.0%)
Nomura Asset Management Co., Ltd. (6.0%)
Government of Japan (5.0%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
Nippon Life Insurance Co. (3.2%)
Eisai Co., Ltd. (3.2%)
Asset Management One Co., Ltd. (3.0%)
Nikko Asset Management Co., Ltd. (2.9%)
Daiwa Asset Management Co. Ltd. (2.8%)
The Vanguard Group, Inc. (2.2%)

Contact Details

Website:http://www.eisai.co.jp
Address: 4-6-10 Koishikawa, Bunkyo-Ku, Tokyo, 112-8088, Japan
Phone: +81.3.3817.3700

Related Companies

Eisai Innovation, Inc.
Eisai Europe Ltd.
Eisai LLC
Eisai Machinery China Co. Ltd.
Eisai Laboratorios S de RL de CV
Eisai GesmbH
Eisai Farmaceutica, Unipessoal Lda.
Eisai Clinical Research Singapore Pte Ltd.
Eisai Ltd. (Canada)
Eisai SA/NV
Eisai (Malaysia) Sdn. Bhd.
Eisai (Thailand) Marketing Co., Ltd.
Eisai AB
Eisai Pharma AG
Eisai (Singapore) Pte Ltd.
Eisai Co. Ltd. /Misato Factory/
Eisai Board Incentive Plan
Eisai Corporate Pension Fund
Eisai Pension Fund
Eisai China, Inc.
H3 Biomedicine, Inc.
Eisai R&D Management Co., Ltd.
Herusu Co., Ltd.
Gakuen Shoji Co., Ltd.
PT Eisai Indonesia
Eisai Taiwan, Inc.
Eisai (Hong Kong) Co., Ltd.
Eisai Australia Pty Ltd.
Eisai Pharmaceuticals India Pvt Ltd.
Eisai GmbH

Competitors

JW Holdings Corporation
Ipsen SA
Ventyx Biosciences, Inc.
Denali Therapeutics Inc.
Immutep Ltd
JW Pharmaceutical Corporation
Morphic Holding, Inc.
Mirati Therapeutics Inc.
Exelixis, Inc.
Codiak BioSciences, Inc.
Blueprint Medicines Corp.
Arcutis Biotherapeutics Inc
Prometheus Biosciences, Inc
Aprea Therapeutics, Inc.
Verastem, Inc.
Cortexyme, Inc.
Ikena Oncology, Inc.
Iovance Biotherapeutics Inc
TCR2 Therapeutics, Inc.
Tyra Bioscience, Inc
Aeolus Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc.
AC Immune SA
Vivoryon Therapeutics N.V.
Xenon Pharmaceuticals Inc.
Prothena Corp. Plc
Vaxxinity Inc Class A
Aptinyx Inc
NeuroBo Pharmaceuticals, Inc.
Cyclerion Therapeutics,Inc.

Last Updated on 5 Jul, 2022